<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220920055998N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-02-12</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>evaluate the effectiveness of  Emotion-Focused therapy in PMDD</public_title>
      <acronym>PMDD</acronym>
      <scientific_title>evaluate the effectiveness of Emotion-Focused therapy on outcome treatment in premenstrual dysphoric disorder</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-04-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>48</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67772</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Factorial, Purpose: Treatment, Randomization description: People are assigned to the   Emotion-Focused therapy group and the control group by block randomization method. For this purpose, 4 blocks will be used, which will be designed using a random number table, and the allocation of people to the control and intervention groups will be done based on the sequence of the randomization table, which the statistical consultant and the interventionist are aware of, Blinding description: The evaluator and statistical analyst are blind to the research process, but the researcher and the participants are not blind to the research.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Premenstrual Dysphoric Disorder.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In this research, Emotion-Focused Therapy was done individually. To start the Emotion-Focused Therapy, first in a meeting, we talked about the objectives of the research, the principles of secrecy and confidentiality of the participants' information, possible side effects, and the rules of participation in the research. Then, explanations were provided about Pre Menstrual Dysphoric Disorder, available treatments for it and their differences, types of interventions for this disorder, Emotion-Focused Therapy and its effectiveness, duration of sessions, number of sessions, and how to end them. Before the first session, the participants completed the research questionnaires as a pre-test and then entered the treatment.16 treatment sessions, each session 45 minutes, were held weekly. The treatment had three main stages.The first phase refers to an initial stage of treatment, which is focused onestablishing a therapeutic bond and promoting client awareness. This is centered onbuilding a safe and empathic therapeutic alliance and relationship, as well as setting ashared focus for the process, which allows clients to shift their attention inwards andbecome more aware of their experiences.In the second phase, focused on theevocation and exploration of core difficulties of emotional processing, the main goalis to help clients experience their core vulnerabilities by attending, arousing and exploring their maladaptive schemes. Gradual exploration of these experiences allowsreaching to the core experiences of vulnerability. In this phase, therapist and clientwork together in order to access and process the “core pain”.The third and final phase, focused on emotion transformation, involves theconstruction of alternatives by producing new emotions and building new alternativesand meanings. Intervention 2: Control group: In the control group, the waiting list method was used to comply with ethical principles. After completing the treatment, the questionnaires were given again to the people of both groups, and the follow-up will be done after three months. Then, Emotion-Focused Therapy will be done individually by the researcher for the subjects of the control group who are willing to participate in the treatment.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is The study has not been completed.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Saeideh Izadi Dehnavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>shahid Mansouri Sreet, Niyayesh Sreet, Satarkhan Avenue</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1145613111</zip>
        <telephone>+98 21 6655 5516</telephone>
        <email>s.izadipsy@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Saeideh Izadi Dehnavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Mansouri Sreet, Niyayesh Sreet, Satarkhan Avenue</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613111</zip>
        <telephone>0982166555516</telephone>
        <email>S.izadipsy@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Diagnosis of PMDD disorder based on SCID-5
Regular menstrual cycle (25 to 32 days)
Minimum education is diploma</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>44 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Pregnancy (within the last 6 months)
Breastfeeding (during the last 6 months)
Menopause
Having certain medical diseases (cardiac, respiratory, neurological diseases, high blood pressure, migraine, hormonal problems) according to the subject's self-report.
Having any psychiatric disorder for which a person takes medicine
Use of hormonal contraceptive methods
Drug abuse</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F38.8</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other specified mood [affective] disorders</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In this research, Emotion-Focused Therapy was done individually. To start the Emotion-Focused Therapy, first in a meeting, we talked about the objectives of the research, the principles of secrecy and confidentiality of the participants' information, possible side effects, and the rules of participation in the research. Then, explanations were provided about Pre Menstrual Dysphoric Disorder, available treatments for it and their differences, types of interventions for this disorder, Emotion-Focused Therapy and its effectiveness, duration of sessions, number of sessions, and how to end them. Before the first session, the participants completed the research questionnaires as a pre-test and then entered the treatment.16 treatment sessions, each session 45 minutes, were held weekly. The treatment had three main stages.The first phase refers to an initial stage of treatment, which is focused onestablishing a therapeutic bond and promoting client awareness. This is centered onbuilding a safe and empathic therapeutic alliance and relationship, as well as setting ashared focus for the process, which allows clients to shift their attention inwards andbecome more aware of their experiences.In the second phase, focused on theevocation and exploration of core difficulties of emotional processing, the main goalis to help clients experience their core vulnerabilities by attending, arousing and exploring their maladaptive schemes. Gradual exploration of these experiences allowsreaching to the core experiences of vulnerability. In this phase, therapist and clientwork together in order to access and process the “core pain”.The third and final phase, focused on emotion transformation, involves theconstruction of alternatives by producing new emotions and building new alternativesand meanings.</i_keyword>
      <i_keyword>Control group: In the control group, the waiting list method was used to comply with ethical principles. After completing the treatment, the questionnaires were given again to the people of both groups, and the follow-up will be done after three months. Then, Emotion-Focused Therapy will be done individually by the researcher for the subjects of the control group who are willing to participate in the treatment.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity of symptoms in Premenstrual Dysphoric Disorder. Timepoint: Before the intervention, the last session, 3 months after the intervention. Method of measurement: Premenstrual Symptoms Screening Tool-PSST.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Difficulties in Emotion Regulation. Timepoint: Before the intervention, the last session, 3 months after the intervention. Method of measurement: Difficulties in Emotion Regulation Scale (DERS).</sec_outcome>
      <sec_outcome>Severity of symptoms of anxiety, depression, stress. Timepoint: Before the intervention, the last session, 3 months after the intervention. Method of measurement: Depression, Anxiety, Stress Scale-21 (DASS-21).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-01-26</approval_date>
        <contact_name>Ethic committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Iran University of Medical Sciences ,fifth floor Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
